Drug Prior Authorization Committee Meeting Information
2023
- Drug PA Agenda
- MO Pharmacy Advisory Board Slides Oct. 2023
- Edit Implementation Schedule
- New Drug Edits with No Changes
- PDL Announcements
- PDL Recommendations
- Conduent Reports
- Clinical Edit Proposals – Existing Criteria
- Alpelisib
- Emsam
- Entresto
- Immunoglobulins (IVIG and SCIG)
- Narcolepsy Inhibitors
- Nuedexta
- Palforzia
- Parathyroid Hormone and Bone Resorption Suppression Related Agents
- Sickle Cell Disease
- Spinal Muscular Atrophy (SMA)
- SSRI Step Therapy
- Transthyretin-Mediated Amyloidosis (ATTR)
- Xcopri
- Clinical Edit Proposals - New or Revised Criteria
- Botulinum Toxin
- Diagnosis Code Required Policy
- Enzyme Deficiency, Select Agents
- Generalized Myasthenia Gravis
- Lambert-Eaton Myasthenic Syndrome (LEMS)
- Psychotropic Medications Polypharmacy
- Ranolazine
- RSV Prophylaxis – Pediatric
- Skyclarys
- SNRI
- Vyjuvek
- Preferred Drug List Edit Proposals – Existing Criteria
- ACE Inhibitors/Calcium Channel Blocker Combinations
- ADHD, Amphetamines Short Acting
- ADHD, Methylphenidate Short Acting
- ADHD, Non-Stimulants
- Angiotensin Receptor Blocker/Calcium Channel Blocker Combinations
- Anticonvulsants, Rescue Agents
- Antiplatelet Agents
- Beta Adrenergic Blockers & Beta Adrenergic Blockers/Diuretic Combinations
- Bone Ossification Agents
- Calcium Channel Blockers, Dihydropyridine
- Direct Renin Inhibitors & Combinations
- Electrolyte Depleting Agents, Phosphate Lowering
- Niacin Derivatives
- Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors
- Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRAs)
- Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Inhaled
- Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Injectable
- Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Oral
- Triglyceride Lowering Agents
- Preferred Drug List Edit Proposals – New or Revised Criteria
- ACE Inhibitors and ACE Inhibitors/Diuretic Combinations
- ADHD, Amphetamines Long Acting
- ADHD, Methylphenidate Long Acting
- Angiotensin Receptor Blockers and Angiotensin Receptor Blocker/Diuretic Combinations
- Anticoagulants, Oral and Subcutaneous
- Antihyperuricemic Agents
- Benign Prostatic Hyperplasia Agents
- Beta Adrenergic Agents, Short Acting
- Bile Salt Agents
- Calcium Channel Blockers, Non-Dihydropyridine
- Electrolyte Depleting Agents, Potassium Lowering
- Homozygous Familial Hypercholesterolemia (HoFH) Agents
- Keratoconjunctivitis Agents
- Mineralocorticoid Receptor Antagonists (MRA)
- Proton Pump Inhibitors (PPIs)
- Pulmonary Arterial Hypertension (PAH) Agents, Phosphodiesterase-5 (PDE5) and Soluble Guanylate Cyclase (SGC) Stimulators
- Statins (HMG-CoA Reductase Inhibitors) and Combinations
- Sympatholytics
- Urea Cycle Disorder Agents
- Agenda
- Minutes
- Edit Implementation Schedule
- New Drugs Edits
- PDL Announcements
- PDL Recommendations
- Conduent Reports
- MO Pharmacy Advisory Board Slides
- Clinical Edit Proposals - Existing Criteria
- Ampyra
- Besremi
- C5 Complement Inhibitors
- CAR-T Cell
- Crysvita
- DMD
- Gamifant
- Iron-Injectable
- Koselugo
- Luxturna
- NMOSD
- Reblozyl
- TIMS, Small Molecule JAK Inhibitor
- Tolvaptan
- Vyvgart
- Zometa
- Clinical Edit Proposals - New or Revised Criteria
- Daybue
- Enjaymo
- Filspari
- Givlaari
- Joenja
- Synagis
- Tepezza
- Preferred Drug List Edit Proposals - Existing Criteria
- Aplha Glucosidase Inhibitors
- Amylin Analogs
- Biguanides & Combination Agents
- Cryopyrin-Associated Periodic Syndrome (CAPS)
- DPPIV
- Erythropoiesis Stimulating Agents
- GLP-1s and Combination Agents
- Insulin, Mixed
- Insulin, Non-Analogs
- Insulin, Rapid Acting
- LHRH, GnRH Agents, Oral
- Meglitinides
- Methotrexate Agents
- Psoriasis Agents, Oral
- Sulfonylurea Agents, 2nd Generation
- Thiazolidinediones & Combos
- TIMs, IL17 Receptor Antagonists
- TIMs, IL23-12 Inhibitors
- Preferred Drug List Edit Proposals - New or Revised Critera
- Atopic Dermatitis Agents, Immunomodulators
- Bleeding Disorder Agents
- Colony Stimulating Factors
- Growth Hormone Agents, Somatropin
- Growth Hormone Releasing Factors, Select Agents
- Insulin, Long Acting
- LHRH, GnRH Agents, Non-Oral
- Multiple Sclerosis Agents, Injectable
- Multiple Sclerosis Agents, Oral
- Psoriasis Agents, Topical
- SGLT Inhibitors
- Thrombocytopenia Agents
- TIMs, IL6 Receptor Inhibitors
- TIMs, JAK Inhibitors
- TIMs, Misc Allergy & Asthma Related Monoclonal Antibodies
- TIMs, Select Agents
- TIMs, TNF Inhibitors
- Urinary Tract Antispasmodics
- Agenda
- Minutes
- Edit Implementation Schedule
- New Drugs Edits
- PDL Announcements
- PDL Recommendations
- Conduent Reports
- Missouri Board of Pharmacy Continuing Education
- MO Pharmacy Advisory Board Slides April 2023
- Clinical Edit Proposals – No New Criteria:
- Acne and Rosacea – Select Topical Agents Step Therapy Edit
- Fabry Disease
- Givlaari
- Imcivree
- Isturisa
- Megestrol Acetate
- Nulibry
- Oxervate
- Oxlumo
- Scenesse
- Sickle Cell Disease
- Spravato
- Systemic Antifungals
- Tavneos
- Voxzogo
- Zokinvy
- Zulresso
- Preferred Drug List Edit Review – Existing Criteria:
- Actinic Keratosis Agents, Topical
- Androgenic Agents
- Antibiotics, Inhaled
- Anticholinergics, Long Acting Beta Adrenergic (LABA) Combinations
- Anticholinergics, Short Acting and Combinations Inhaled
- Antifungals, Topical
- Antihistamines and Antihistamine/Decongestant Combinations, 2nd Generation
- Antihistamines, Intranasal
- Antiparasitics, Topical
- Antivirals, Herpes Oral
- Benzoyl Peroxide/Antibiotic Combinations
- Beta Adrenergic Agents, Nebulized
- Beta Adrenergic Agents, Short Acting
- Corticosteroids, Ophthalmic “Soft”
- Corticosteroids, Oral Inhaled
- Corticosteroids, Topical
- Cough and Cold Preparations
- Fluoroquinolones, Ophthalmic
- Fluoroquinolones, Otic
- Hepatitis C Agents
- Leukotriene Receptor Modifiers
- Mast Cell Stabilizers, Ophthalmic
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Ophthalmic
- Pancreatic Enzyme Agents
- Retinoids, Topical
- Preferred Drug List Edit – New Criteria or Revision of Existing Criteria:
- Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors
- Anticholinergics, Long Acting Inhaled
- Antifungals, Oral
- Antihistamines, Ophthalmic
- Antivirals, Tropical
- Beta Adrenergic Agents, Long Acting
- Corticosteroids & Rhinitis Agents, Intranasal
- Epinephrine Agents, Self-Injectable
- Glaucoma Agents
- Inflammatory Bowel Disease Agents, Oral
- Inflammatory Bowel Disease Agents, Rectal
2022
- December DPAC Meeting Minutes
- Agenda
- Edit Implementation Schedule
- PDL Recommendations
- PDL Announcements DPAC 2023
- New Drugs Edits With No Annual Changes
- Dec DPA 2022 - Jan DUR 2023 Reports
- PA DUR Slides December 2022
- Clinical Edit Proposals - No New Criteria:
- Aduhelm Clinical Edit
- Antipsychotics, 1st Generation (Typical) Clinical Edit
- Benzodiazepine, Select Oral Clinical Edit
- Butalbital Combinations without Codeine Clinical Edit
- Corlanor Clinical Edit
- Empaveli Clinical Edit
- HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit
- High Risk Therapies Clinical Edit
- Kerendia Clinical Edit
- Morphine Milligram Equivalent (MME) Accumulation Clinical Edit
- Non-Oral Contraceptives Fiscal Edit
- Oxazolidinone Fiscal Edit
- Pompe Disease Clinical Edit
- Selzentry Clinical Edit
- Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit
- Verquvo Clinical Edit
- Clinical Edit Proposals - New Criteria or Revision of Existing Criteria:
- Camzyos Clinical Edit
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit
- Opioids Short Acting Clinical Edit
- Skysona Clinical Edit
- Xenpozyme Clinical Edit
- Ztalmy Clinical Edit
- Zynteglo Clinical Edit
- Resource List Edit Review - New Criteria or Revision of Existing Criteria:
- Antipsychotics - 2nd Generation (Atypical) Depot Agents
- Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents
- Preferred Drug List Edit Review - Existing Criteria:
- Alzheimer’s Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit
- Antiemetics, 5-HT3 and NK1 Injectables PDL Edit
- Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit
- Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit
- Anti-Parkinsonism, MAO-B Inhibitors PDL Edit
- Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit
- Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit
- Glucagon Agents PDL Edit
- Hereditary Angioedema Agents PDL Edit
- NSAIDs PDL Edit
- Opioid Emergency Reversal Agents PDL Edit
- Opioids, Long Acting PDL Edit
- Somatostatin Analogs PDL Edit
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit
- Preferred Drug List Edit Review - New Criteria or Revision of Existing Criteria:
- Antiandrogenic Agents PDL Edit
- Anticonvulsants, Dravet Syndrome PDL
- Anti-Migraine, Alternative Oral Agents PDL Edit
- Antiplatelet Agents PDL Edit
- Antiretroviral Therapy (ART) PDL Edit
- Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit
- Fibromyalgia Agents PDL Edit
- GI Motility Agents, Chronic PDL Edit
- Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit
- Neuropathic Pain Agents PDL Edit
- Opioid & Select Alcohol Dependence Agents PDL Edit
- Sedative Hypnotics PDL Edit
- Skeletal Muscle Relaxants PDL Edit
- Tramadol-Like Agents PDL Edit
- September DPAC Minutes
- Agenda
- Edit Implementation Schedule
- PDL Announcement
- PDL Recommendations
- New Drugs and Edits with No Annual Changes
- September DPAC Reports
- Clinical Edit Proposals - No New Criteria:
- Entresto
- Spinal Muscular Atrophy (SMA)
- PDL Proposals - No New Criteria:
- ACEI_ACEI-Diuretic Combinations
- ACEI_CCB Combinations
- ADHD, Methylphenidate SA
- ADHD, Non-Stimulants
- Alpha Glucosidase Inhibitors
- Amylin Analogs
- Antibiotics, Mupirocin Topical
- Antihyperuricemic Agents
- ARB_ARB-Diuretic Combos
- ARB-CCB Combos
- BB_BB-Diuretic Combos
- Benign Prostatic Hyperplasia (BPH) Agents
- Biguanides and Combination Agents
- Bone Ossification Agents
- CCB, Non-DHP
- Cephalosporins
- Direct Renin Inhibitors and Combos
- DPPIV Inhibitors
- Electrolyte Depleting Agents, Phosphate Lowering
- Erythropoiesis Stimulating Agents
- Fluoroquinolones, Oral
- Homozygous Familial Hypercholesterolemia (HoFH)
- Insulin, Mixed
- Insulin, Non-Analogs
- Insulin, Rapid Acting
- Macrolides
- Meglitinides
- Methotrexate Agents
- Niacin Derivatives
- PAH, ETRAs
- PAH, PDE5-SGC
- PAH, Prostacyclins Oral
- Penicillins
- SGLT2 Inhibitors_PDL Proposal_9.15.22
- Statins and Combos
- Sulfonylurea Agents, Second Generation
- Tetracyclines
- Thiazolidinediones and Combinations
- Thrombocytopenia Agents
- Triglyceride Lowering Agents
- PDL Proposals - New Revised Criteria:
- ADHD, Amphetamines long active
- ADHD, Amphetamines Short Acting
- ADHD, Methylphenidate long acting
- Antibiotics, GI Oral
- Antibiotics, Vaginal
- Anticoagulants, Oral and Subcutaneous
- Anticonvulsants, Rescue Agents
- Antiplatelet Agents
- Bile Salt Agents
- CCB, DHP
- Colony Stimulating Factors
- Cryopyrin-Associated Periodic Syndrome (CAPS)
- Dry Eye Disease Agents
- Electrolyte Depleting Agents, Potassium Lowering
- GLP-1 Receptor Agonists and Combination Agents
- Growth Hormone Agents, Somatropin
- Growth Hormone and Growth Hormone Releasing Factors, Select Agents
- Insulin, Long Acting
- LHRH, GnRH Agents, Non-Oral
- LHRH, GnRH Agents, Oral
- Multiple Sclerosis Agents, Injectable
- Multiple Sclerosis Agents, Oral
- PAH, Prostacyclins Inhaled
- PAH, Prostacyclins Injectable
- PCSK9 Inhibitors
- Proton Pump Inhibitors (PPIs)
- Sympatholytics
- Targeted Immune Modulators JAK Inhibitors
- Targeted Immune Modulators, IL6 Receptor Inhibitor
- Targeted Immune Modulators, IL17 Receptor Antagonists
- Targeted Immune Modulators, IL23-12 Inhibitors
- Targeted Immune Modulators, Misc Allergy and Asthma Related Monoclonal Antibodies
- Targeted Immune Modulators, Select Agents
- Targeted Immune Modulators, TNF Inhibitors
- Urinary Tract Antispasmodics
- Approved Meeting Minutes
- Agenda
- Edit Implementation Schedule
- PDL Announcements
- June DPAC Reports
- New Drugs and Edits With No Annual Changes
- Clinical Edit Proposals – No New Criteria:
- Ampyra
- ATTR
- Botulinum Toxin
- Crysvita
- DMD
- Emsam
- Gamifant
- Immunoglobulin
- Koselugo
- Luxturna
- Narcolepsy Inhibitors
- NMOSD
- Nuedexta
- Oxandrin
- Palforzia
- Palynziq
- Ranexa
- Reblozyl
- SSRI
- Synagis
- Tepezza
- Tolvaptan
- Xcopri
- Zometa
- Clinical Edit Proposals – New Revised Criteria:
- Besremi
- CAR-T Cell
- Enjaymo
- Enzyme Deficiency, Select Agents
- Iron – Injectable
- LEMS
- Manufacturers Requiring PA
- PolyPharm
- PTH and Other Agents
- SNRI
- TIMS, Small Molecule JAK Inhibitor
- Vyvgart
- Approved Minutes
- Agenda
- Edit Implementation Schedule
- PDL Announcements
- PDL Recommendations
- New Drugs & Edits with No Annual Changes Presentation
- March DPAC Reports
- Asthma Policy Update
- Clinical Edit Proposals – No New Criteria:
- Imcivree
- Megestrol Acetate
- Nulibry
- Oxervate
- Oxlumo
- Spravato
- Zokinvy
- Zulresso
- Clinical Edit Proposals – New Revised Criteria:
- Acne or Rosacea - Select Topical Agents
- C5 Complement Inhibitors
- CFTR Modulators
- Fabry Disease
- Givlaari
- Isturisa
- Scenesse
- Sickle Cell Disease
- Systemic Antifungals
- Tavneos
- Voxzogo
- PDL Proposals – No New Criteria:
- Actinic Keratosis Agents, Topical
- Androgenic Agents
- Antibiotics, Inhaled
- Antifungals, Oral
- Antifungals, Topical
- Antihistamines and Antihistamine-Decongestant Combinations, Second Generation
- Antihistamines, Intranasal
- Antivirals, Herpes Oral
- Antivirals, Topical
- Benzoyl Peroxide-Antibiotic Combinations
- Corticosteriods, Oral Inhaled
- Corticosteroids and Rhinitis Agents, Intranasal
- Corticosteroids, Topical
- Cough-Cold Preparation
- Epinephrine Agents, Self-Injectable
- Fluoroquinolones, Ophthalmic
- Fluoroquinolones, Otic
- Glaucoma Agents
- Mast Cell Stabilizers, Ophthalmic
- NSAIDS, Ophthalmic
- Psoriasis Agents, Oral
- Psoriasis Agents, Topical
- Retinoids, Topical
- Ulcerative Colitis Agents, Oral
- Ulcerative Colitis Agents, Rectal
- PDL Proposals – New Revised Criteria:
- Anticholinergics LABAs-ICS Combinations and PDE4 Inhibitors
- Anticholinergics, Long Acting Beta Adrenergics Combinations
- Anticholinergics, Long Acting Inhaled
- Anticholinergics, Short Acting and Combinations Inhaled
- Antihistamines, Ophthalmic
- Antiparasitics, Topical
- Atopic Dermatitis Agents, Immunomodulators
- Beta Adrenergic Agents, Short Acting
- Beta Adrenergic Agents, Long Acting
- Beta Adrenergic Agents, Nebulized
- Corticosteroids, Ophthalmic Soft
- Hepatitis C Agents
- Leukotriene Receptor Modifiers
- Pancreatic Enzymes
- Respiratory Monoclonal Antibodies
2021
- Draft Minutes
- Agenda
- Edit Implementation Schedule
- PDL Recommendations
- PDL Announcements
- New Drugs & Edits with No Annual Changes Presentation
- December 2021 – January 2022 DPAC Reports
- Opioid Policy Review Edits:
- High Risk Therapies
- MHD Opioid Policy Update
- MME
- Opioid Dependence Agents
- Opioid Emergency Reversal Agents
- Opioids - Long Acting
- Opioid - Short Acting
- TIRF
- Tramadol-Like Agents
- Clinical Edit Proposals – No New Criteria:
- 15 Day Supply Oral Oncology
- Butalbital Combo without Codeine
- Butalbital Combo Excessive Therapy
- Diabetic Supply Quantity Limitation
- Out of State Pharmacies
- Selzentry
- Clinical Edit Proposals – New Revised Criteria:
- 15 Day Supply
- Antipsychotics, 1st Gen (Typical)
- Antipsychotics, 2nd Gen (Atypical)
- APAP Accumulation
- Benzodiazepines - Select Oral
- BiDil
- Biosimilar vs Reference Products
- Corlanor
- Empavel
- Extended Supply
- High Cost Medications
- Kerendia
- Non-Oral Contraceptives
- Pompe Disease
- Spinal Muscular Atrophy (SMA)
- PDL Proposals – No New Criteria:
- Alzheimer's Agents
- Anticonvulsants, Dravet Syndrome
- Antiemetics, THC Derivatives
- Anti-Parkinsonism, MAO-B Inhibitors
- Anti-Parkinsonism, Non-Ergot Dopamine Agonists
- GI Motility Agents, Chronic
- Sedative Hypnotics
- Somatostatin Analogs
- PDL Proposals – New Revised Criteria:
- Antiandrogenic Agents
- Antiemetics, 5-HT3 and NK1 Injectables
- Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables
- Anti-Migraine, Alternative Oral Agents
- Anti-Migraine, Serotonin (5-HT1) Receptor Agonists
- Antiretroviral Therapy (ART)
- Bile Salt Agents
- Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- CDK4-6 Inhibitors
- Fibromyalgia Agents
- Glucagon Agents
- Hereditary Angioedema Agents
- Homozygous Familial Hypercholesterolemia (HoFH)
- Neuropathic Pain Agents
- NSAIDs
- Skeletal Muscle Relaxants
- VMAT2 Inhibitors
- Minutes
- Agenda
- Edit Implementation Schedule
- PDL Announcements
- PDL Recommendations
- MHD Pharmacy Program & Budget Update
- New Drugs & Edits With No Annual Changes Presentation
- Conduent Reports:
- September 2021 DPAC Reports
- PDL Proposals – No New Criteria:
- Angiotensin Receptor Blocker/Angiotensin Receptor Blocker Combo
- Angiotensin Receptor Blocker/Calcium Channel Blocker Combo
- Beta Adrenergic Blocker/Beta Adrenergic Blockers/Diuretic Combo
- Calcium Channel Blockers, Dihydropyridines
- Calcium Channel Blockers, Non-Dihydropyridine
- Direct Renin Inhibitors
- Dry Eye Disease Agents
- Niacin Derivatives
- PAH Agents, ETRAs
- PAH Agents, Prostacylin Pathway Agonists, Inhaled
- PAH Agents, Prostacyclin Pathway Agonists, Oral
- Sympatholytic Agents
- PDL Proposals – New Revised Criteria:
- ACE Inhibitors and ACE Inhibitors/Diuretic Combo
- ACE Inhibitor/Calcium Channel Blocker Combinations
- ADHD, Amphetamines Long Acting
- ADHD, Amphetamines Short Acting
- ADHD, Methylphenidate Long Acting
- ADHD, Methylphenidate Short Acting
- ADHD, Non-Stimulant Agents
- Anticoagulant Agents, Oral and Subcutaneous
- Anticonvulsants, Rescue Agents
- Antiplatelet Agents
- Homozygous Familial Hypercholesterolemia Agents
- PAH Agents, PDE5 and SGC Stimulators
- PAH Agents, Prostacyclin Pathway Agonists, Injectable
- PCSK9 Inhibitors
- Proton Pump Inhibitors
- Statins and Combinations
- Triglyceride Lowering Agents
- Clinical Edits – No New Criteria:
- Emsam
- Immunoglobulins
- Lambert-Eaton Myasthenic Syndrome
- Neuromyelitis Optica Spectrum Disorder
- Nuedexta
- Oxandrin
- Palforzia
- Ranexa
- Transthyretin-Mediated Amyloidosis
- Xcopri
- Clinical Edits – New Revised Criteria:
- Aduhelm
- Botulinum Toxin
- Equetro
- Narcolepsy Inhibitors
- Psychotropic Medications Polypharmacy
- Serotonin and Norepinephrine Reuptake Inhibitors
- Selective Serotonin Reuptake Inhibitor
- Minutes
- Agenda
- New Drugs
- Edit Implementation Schedule
- PDL Recommendations
- PDL Announcements
- Conduent Reports:
- June 2021 DPAC Reports
- CyberAccess User Statistics
- PDL Proposals – No New Criteria
- Amylin Analogs
- Antibiotic, Vaginal
- Bile Sale Agents
- Cephalosporin Agents
- Electrolyte Depleting Agents, Phosphate Lowering
- Electrolyte Depleting Agents, Potassium Lowering
- Fluoroquinolone Agents, Oral
- Insulin, Mixed
- Insulin, Non-Analogs
- Penicillin Agents
- Sulfonylurea Agents, Second Generation
- Targeted Immune Modulators, IL6 Receptor Inhibitors
- Thrombocytopenia Agents
- PDL Proposals – New Revised Criteria
- Alpha Glucosidase Inhibitors
- Antibiotics, GI Oral
- Antibiotics, Mupirocin Topical
- Antihyperuricemic Agents
- Benign Prostatic Hyperplasia Agents
- Biguanides
- Bone Ossification Agents
- Colony Stimulating Factors
- Cryopyrin-Associated Periodic Syndrome (CAPS)
- DPPIV Inhibitor
- Erythropoiesis Stimulating Agents
- GLP-1 Agonists
- Growth Hormone Agents, Somatropin
- Growth Hormone, Growth Hormone Releasing Factors, Select Agents
- Insulin, Long Acting
- Insulin, Rapid Acting
- LHRH_GnRH Agents, Non-Oral
- Macrolide Agents
- Meglitinide Agents
- Methotrexate Agents
- Multiple Sclerosis Agents, Injectable
- Multiple Sclerosis Agents, Oral
- SGLT2 Inhibitors
- Targeted Immune Modulators, IL17
- Targeted Immune Modulators, IL23 IL12 inhibitors
- Targeted Immune Modulators, JAK Inhibitors
- Targeted Immune Modulators, Select Agents
- Targeted Immune Modulators, TNF Inhibitors
- Tetracycline Agents
- Thiazolidinediones
- Urinary Tract Antispasmodics
- Clinical Edits – No New Criteria:
- Ampyra
- Elagolix
- Gamifant
- Koselugo
- Luxturna
- Oxervate
- Reblozyl
- Synagis
- Tepezza
- Tolvaptan
- Zometa
- Clinical Edits – New Revised Criteria
- CAR-T Cell
- Crysvita
- DMD
- Entresto
- Extended Supply
- HBV Nucleotide Analog
- Imcivree
- Iron – Injectable
- Nulibry
- Oxazolidinone
- Palynziq
- PTH and Other Agents
- Verquvo
- Zokinvy
- Clinical Edit Proposals-No New Criteria
- Acne or Rosacea – Select Topical Agents
- Givlaari
- Megestrol
- Sickle Cell Disease
- Systemic Antifungals
- Zulresso
- Clinical Edit Proposals-New Revised Criteria
- CFTR
- Clobazam Agents
- Fabry Disease
- Nocturnal Polyuria
- Opioids – Single Agent Short Acting
- Oxlumo
- Spravato
- PDL Proposals-No New Criteria
- Actinic Keratosis Agents, Topical
- Antifungals, Oral
- Antihistamines, Intranasal
- Antihistamines-Decongestant Combinations, Second Generation
- Antivirals, Oral
- Antivirals, Topical
- Benzoyl Peroxide-Antibiotic Combinations
- Beta Adrenergic Agents, Long Acting
- Beta Adrenergic Agents, Nebulized
- Cough-Cold Preparations
- Fluoroquinolones, Ophthalmic
- Mast Cell Stabilizers, Ophthalmic
- NSAIDS, Ophthalmic
- Pancreatic Enzymes
- Psoriasis Agents, Oral
- Psoriasis Agents, Topical
- Retinoids, Topical
- Ulcerative Colitis Agents, Rectal
- PDL Proposals-New Revised Criteria
- Androgenic Agents
- Antibiotics, Inhaled
- Antifungals, Topical
- Antihistamines, Ophthalmic
- Antiparasitics, Topical
- Atopic Dermatitis Agents, Immunomodulators
- Beta Adrenergic Agents, Short Acting
- COPD Agents
- Corticosteroids, Inhaled
- Corticosteroids, Intranasal
- Corticosteroids, Ophthalmic Soft
- Corticosteroids, Topical
- Epinephrine Agents, Self-Injectable
- Fluoroquinolones, Otic
- Glaucoma Agents
- Hepatitis C Agents
- Hereditary Angioedema (HAE)
- Leukotriene Receptor Modifiers
- Respiratory Monoclonal Antibodies
- Ulcerative Colitis Agents, Oral
2020
- Minutes
- Agenda - Webex only. See agenda for call in details.
- Edit Implementation Schedule
- PDL Recommendations
- PDL Announcements
- Conduent Reports:
- FY21 Top 25 Drugs Quarterly Report
- CyberAccess User Statistics
- Helpdesk Status Report
- Logging Table
- New Drug Summary
- PDL Proposals - New Revised Criteria:
- Anticonvulsants, Dravet Syndrome
- Antiemetic 5HT3, NK1 Agents, Injectable
- Anti-Migraine Alternative Oral Agents
- Anti-Migraine 5HT1 Agents
- Anti-Parkinsonisms Non-Ergot Dopamine Agonists
- Antiretroviral Reference Products
- Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- CDK4-6 Inhibitors
- Fibromyalgia Agents
- GI Motility Agents
- Glucagon Agents
- Neuropathic Pain
- NSAID Agents
- Opioid Dependence Agents
- Opioids Long Acting
- Sedative Hypnotics
- Skeletal Muscle Relaxants
- Somatostatic Analogs
- Tramadol-Like Agents
- VMAT2 Inhibitors
- PDL Proposals - No New Criteria:
- Alzheimer’s Agents
- Antiandrogenic Agents
- Antiemetic 5HT3, NK1, Other Non-Injectable Agents
- Antiemetic THC Derivative Agents
- Anti-Parkinsonism, MAO-B Inhibitor Agents
- Hereditary Angioedema
- Opioid Emergency Reversal Agents
- Clinical Edit Proposals - No New Criteria:
- 15 Day Supply Oral Oncology
- APAP Accumulation
- BiDil
- Butalbital Combo without Codeine
- Butalbital Combo Excessive Therapy
- Corlanor
- Entresto
- Selzentry
- Clinical Edit Proposals - New Revised Criteria:
- 15 Day Supply
- Antipsychotics, 1st Gen (Typical)
- Antipsychotics, 2nd Gen (Atypical)
- Benzodiazepines Select Oral
- Biosimilar vs Reference
- Car T Cell
- Diabetic Supply Quantity
- DMD
- High Cost Medication Kits
- High Risk Therapies
- Isturisa
- MME
- NMOSD
- Non-Oral Contraceptives
- Opioids Combos-Short Acting
- Opioids Single Agent-Short Acting
- Out of State Pharmacies
- PolyPharm
- PrEP
- SMA
- TIRF
- Agenda - Webex only. See agenda for call in details.
- Edit Implementation Schedule
- New Drugs
- PDL Recommendations
- Preferred Drug List Announcement
- Conduent Reports:
- CyberAccess User Statistics
- Top 25 Drugs Quarterly Reports
- Helpdesk Status Report
- Logging Table
- New Drug Summary
- Proposed PDL Fiscal Edits:
- ACEI, ACEI-DIURETIC Combos
- ACEI-CCB Combos
- ADHD Amphetmaines Long Acting
- ADHD Amphetmaines Short Acting
- ADHD Methylphenidate Long Acting
- ADHD Methylphenidate Short Acting
- ADHD Non-Stimulants
- Anticoagulants
- Anticonvulsants Rescue Agents
- Antiplatelets
- ARB, ARB-Diuretic Combos
- ARB-CCB Combos
- BetaBlockers and Combos
- CCB-DHP
- CCB-NDHP
- Direct Renin inhibitors Combos
- Dry Eye PDL
- HFHC
- Niacin Derivatives
- PAH ETRAS
- PAH PDE5-SCG
- PAH Prostacyclins Inhaled
- PAH Prostacyclins Injectable
- PAH Prostacyclins Oral
- PCSK-9
- PPI PDL
- Statins
- Sympatholytics
- Triglyceride Lowering Agents
- Conduent Reports:
- CyberAccess User Statistics
- Help Desk Status Report
- Logging Table
- New Drug Summary
- Top 20 Drugs Quarterly Report
- Proposed PDL Fiscal Edits:
- Alpha-Glucosidase Inhibitors PDL Edit
- Amylin Analogs PDL Edit
- Antibiotics, Gastrointestinal (GI), Oral Agents PDL Edit
- Antibiotics, Vaginal Agents PDL Edit
- Antihyperuricemic Agents PDL Edit
- Anti-Migraine Agents, Alternative Oral Agents PDL Edit
- Bile Salt Agents PDL Edit
- Bone Ossification Agents PDL Edit
- Benign Prostatic Hyperplasia Agents PDL Edit
- Cryopyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit
- Cephalosporins PDL Edit
- Colony Stimulating Factors PDL Edit
- DPP-IV Inhibitors & Combination Agents PDL Edit
- Electrolyte Depleters, Phosphate Lowering Agents PDL Edit
- Electrolyte Depleters, Potassium Lowering Agents PDL Edit
- Erythropoiesis Stimulating Agents PDL Edit
- Fluoroquinolones, Oral PDL Edit
- Growth Hormones & Growth Hormone Releasing Factors, Select Agents PDL Edit
- Growth Hormones, Somatropin Agents Edit
- Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit
- Hepatitis C Agents PDL Edit
- Insulins, Long Acting PDL Edit
- Insulins, Mixed PDL Edit
- Insulins, Non-Analogs PDL Edit
- Iron - Injectable Step Therapy Edit
- Insulins, Rapid Acting PDL Edit
- Macrolides PDL Edit
- Meglitinides PDL Edit
- Methotrexate Agents PDL Edit
- Multiple Sclerosis, Injectable Agents PDL Edit
- Multiple Sclerosis, Oral Agents PDL Edit
- Penicillins PDL Edit
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Edit
- Sulfonylureas, 2nd Generation PDL Edit
- Tetracyclines PDL Edit
- Thiazolidinediones & Combination Agents PDL Edit
- Thrombocytopenia Agents PDL Edit
- Targeted Immune Modulators, Interleukin-6 (IL-6) Receptor Inhibitors PDL Edit
- Targeted Immune Modulators, Interleukin (IL)-17 Antibody/IL17 Receptor Antagonists, IL-23 Inhibitors and IL-23/IL-12 Inhibitors PDL Edit
- Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit
- Targeted Immune Modulators, Select Agents PDL Edit
- Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL Edit
- Urinary Tract Antispasmodics PDL Edit
- Proposed Clinical Fiscal Edits:
- Ampyra® Clinical Edit
- Crysvita® Clinical Edit
- Diacomit® Clinical Edit
- Gamifant® Clinical Edit
- Iron - Injectable Step Therapy Edit
- Koselugo™ Clinical Edit
- Luxturna® Clinical Edit
- Orilissa® Clinical Edit
- Oxervate® Clinical Edit
- Palynziq™ Clinical Edit
- Parathyroid Hormone and Bone Resorption Suppression Related Agents Clinical Edit
- Reblozyl® Clinical Edit
- Synagis® Clinical Edit
- Tepezza™ Clinical Edit
- Tolvaptan Clinical Edit (formerly Jynarque® Clinical Edit)
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors Clinical Edit
- Minutes
- Acne and Rosacea - Select Topical Agents Step Therapy Edit
- Actinic Keratosis Agents - Topical PDL Edit
- Androgenic Agents PDL Edit
- Antibiotic Agents - Inhaled PDL Edit
- Antifungal (Onychomycosis/Candidiasis) Agents - Oral PDL Edit
- Antifungal Agents - Topicals PDL Edit
- Antihistamines/Decongestant Combinations - Low Sedating (2nd Generation) PDL Edit
- Antihistamines - Intranasal PDL Edit
- Antihistamines - Ophthalmic PDL Edit
- Antiparasitic Agents - Topical PDL Edit
- Antivirals - Herpes Oral PDL Edit
- Atopic Dermatitis Agents - Immunomodulators PDL Edit
- Benzoyl Peroxide - Antibiotic Combinations PDL Edit
- Beta Adrenergic Agents - Long Acting PDL Edit
- Beta Adrenergic Agents - Nebulized PDL Edit
- Beta Adrenergic Agents - Short Acting PDL Edit
- Clobazam Agents Clinical Edit
- COPD Anticholinergic Agents PDL Edit
- Corticosteroids Oral - Inhaled PDL Edit
- Corticosteroids and Rhinitis Agents - Intranasal PDL Edit
- Corticosteroids - Ophthalmic “Soft” Steroids PDL Edit
- Corticosteroids - Topical PDL Edit
- Cough and Cold Preparations PDL Edit
- Duchenne Muscular Dystrophy (DMD) Clinical Edit
- Drug PA Agenda
- Drug PA Meeting
- Edit Implementation Schedule
- Epidiolex® (cannabidiol) Clinical Edit
- Epinephrine Self-Injectable Agents PDL Edit
- Fluoroquinolones - Ophthalmic PDL Edit
- Fluoroquinolones - Otic PDL Edit
- Galafold® (migalastat) Clinical Edit
- Givlaari™ (givosiran) Clinical Edit
- Glaucoma Agents PDL Edit
- Leukotriene Modifiers PDL Edit
- Mast Cell Stabilizers - Ophthalmic PDL Edit
- Megestrol Acetate Clinical Edit
- MO Healthnet Pharmacy Program And Budget Update
- New Drugs
- Nocturnal Polyuria Clinical Edit
- Nonsteroidal Anti-Inflammatory Drugs (NSAID) - Ophthalmic PDL Edit
- Pancreatic Enzyme Agents PDL Edit
- Preferred Drug List Announcement
- Psoriasis Agents - Oral PDL Edit
- Psoriasis Agents - Topical PDL Edit
- Reblozyl® (luspatercept-aamt) Clinical Edit
- Retinoids - Topical PDL Edit
- Sickle Cell Disease Clinical Edit
- Spravato® (esketamine) Clinical Edit
- Systemic Antifungals Clinical Edit
- Top 25 Drugs Quarterly Reports
- Ulcerative Colitis Agents ─ Oral PDL Edit
- Ulcerative Colitis Agents ─ Rectal PDL Edit